HLA-B7 Antigen (HLA B7 Antigen)

09/01/1996 - "Tumor-infiltrating lymphocytes (TIL) were isolated from cutaneous melanoma biopsies before and after HLA-B7 gene transfer. "
02/01/1980 - "An alien HLA-B7 was detected in sera from two melanoma patients. "
01/01/1997 - "To determine the safety, toxicity, and efficacy of direct intratumoral injection of an allogeneic major histocompatibility complex (MHC) class I gene, HLA-B7, in a cationic lipid vector (Allovectin-7; Vical Inc, San Diego, CA) in patients with metastatic melanoma. "
01/01/1997 - "Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma."
12/01/1996 - "In hepatic and respiratory cells, transcription of a construct containing the cystic fibrosis transmembrane conductance regulator was observed in more than 80% of the cell population; similarly high levels of plasmid utilization were obtained in studies of HLA-B7 expression in human melanoma cells. "

04/01/2003 - "Human trials of alloantigen gene therapy, using the class I major histocompatibility complex (MHC) HLA-B7, have demonstrated the potential efficacy of this treatment for head and neck cancer. "
05/01/2000 - "Twenty patients with advanced head and neck cancer who had failed conventional therapy and did not express HLA-B7 were treated with gene therapy using a lipid vector by direct intratumoral injection. "
04/01/2004 - "Alloantigen gene therapy with the genes for the Class I major histocompatibility complex (MHC) HLA-B7 and beta 2-microglobulin in HLA-B7-negative patients has potential efficacy in the treatment of head and neck cancer, although the mechanism of response is unclear. "

12/01/2006 - "In sequence, we used algorithm-based predictions, in vivo immunization of HLA-B7 transgenic (Tg) mice, in vitro immunization of human blood lymphocytes from two normal donors and two cancer patients, in vivo processing in HLA-B7 Tg mice and HLA-B7 supertype binding. "
07/01/2002 - "The mean expression of HLA-B7 by autologous tumor cells after gene transfer was 4.53% (range 0.3%-12.1%). "
09/15/2000 - "These CTLs were efficient in killing tumor cells that express HLA-B7 and produce CEA. "
05/01/2000 - "HLA-B7 was demonstrated in the treated tumors, and increased apoptosis was seen in the responding tumors. "
02/01/2000 - "This CTL clone lysed HLA-B7 tumor cells expressing MAGE-A1. "

07/01/2009 - "These results suggest that the MICA-A5 allele appears to confer protection against human breast cancer and that the MICA-A5.1 appears to increase the susceptibility to breast cancer in HLA-B7 patients in our area."
11/15/2005 - "These results support previous suggestions that HLA-B7 is associated with the development of breast cancer in our area."
11/15/2005 - "The HLA-B7 allele confers susceptibility to breast cancer in Spanish women."
11/01/1979 - "A greater incidence of HLA-B7 and B26 was observed in the breast cancer group if compared with the frequency of occurrence of these antigens in the Spanish population. "
07/01/2009 - "Given the association between the HLA-B7 allele and the susceptibility to breast cancer in our area, we also analyzed the distribution of the frequency of the MICA alleles in human leukocyte antigen (HLA)-B7 patients compared with patients with the other alleles. "

10/01/1998 - "Nine patients with advanced head and neck squamous cell carcinoma who had failed conventional therapy and did not express HLA-B7, a class I major histocompatibility complex protein. "
07/01/2001 - "Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck."
07/01/2001 - "To investigate the safety and efficacy of alloantigen plasmid DNA therapy in patients with advanced head and neck squamous cell carcinoma using Allovectin-7 (Vical Inc, San Diego, Calif), a DNA/lipid complex designed to express the class I major histocompatibility complex antigen HLA-B7. "